“If Powerful AI is directed at solving humanity’s hardest problems and the risks are managed responsibly, the potential is ...

Genmab may have arrived in Spain with updated data from a pair of phase 2 studies from the main prize of its Merus buyout, ...

Tango Therapeutics disclosed a 14% reduction in headcount even as the company shared more evidence that its PRMT5 inhibitor ...

Lycia Therapeutics went public with an upsized $317.5 million IPO on Friday, while immunology-focused Windward Bio has also seen which way the public markets are blowing. | Lycia Therapeutics went ...

Incyte has pointed to a spread of phase 1 data for its KRAS G12D inhibitor as proof that the company has a worthy rival to Revolution Medicines in this newly hot cancer space. | Incyte has pointed to ...

Bristol Myers Squibb (BMS) has shared more details with Fierce about the death of a patient who received the pharma's investigational CAR-T in a multiple sclerosis (MS) trial. | Bristol Myers Squibb ...

Boehringer Ingelheim and Microsoft have launched a collaboration to explore the use of AI-powered digital patient twins to improve clinical trial design. | Boehringer Ingelheim and Microsoft have ...

AstraZeneca executives were adamant that detailed data from a phase 3 study of the pharma’s next-generation antibody-drug ...

Bristol Myers Squibb Chief Medical Officer Cristian Massacesi, M.D., has told Fierce that the latest data for its ...

The Big Pharma has already launched a phase 2 trial of JNJ-6143 at a 50 mg daily dose in around 100 patients with metastatic androgen pathway modulation-resistant prostate cancer (mAPMR), an advanced ...

Despite the sweeping scope of the ban covering various types of drug molecules, biopharma business development teams can ...

Roche has shed more light on its investigational KRAS G12C inhibitor's phase 3 victory over Amgen’s Lumakras and Bristol Myers Squibb’s Krazati. | Roche has shed more light on its investigational KRAS ...